SG10202006032VA - Combination therapy based on pd-1 signal inhibitors - Google Patents
Combination therapy based on pd-1 signal inhibitorsInfo
- Publication number
- SG10202006032VA SG10202006032VA SG10202006032VA SG10202006032VA SG10202006032VA SG 10202006032V A SG10202006032V A SG 10202006032VA SG 10202006032V A SG10202006032V A SG 10202006032VA SG 10202006032V A SG10202006032V A SG 10202006032VA SG 10202006032V A SG10202006032V A SG 10202006032VA
- Authority
- SG
- Singapore
- Prior art keywords
- combination therapy
- therapy based
- signal inhibitors
- inhibitors
- signal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
- A61K31/06—Phenols the aromatic ring being substituted by nitro groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015238511 | 2015-12-07 | ||
| JP2016119695 | 2016-06-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202006032VA true SG10202006032VA (en) | 2020-07-29 |
Family
ID=59014100
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201804473RA SG11201804473RA (en) | 2015-12-07 | 2016-12-05 | Pd-1 signal inhibitor combination therapy |
| SG10202006032VA SG10202006032VA (en) | 2015-12-07 | 2016-12-05 | Combination therapy based on pd-1 signal inhibitors |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201804473RA SG11201804473RA (en) | 2015-12-07 | 2016-12-05 | Pd-1 signal inhibitor combination therapy |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20180362650A1 (en) |
| EP (2) | EP3388084A4 (en) |
| JP (1) | JP6994240B2 (en) |
| KR (1) | KR20180093990A (en) |
| CN (3) | CN114404595A (en) |
| AU (1) | AU2016366250A1 (en) |
| BR (1) | BR112018011131A2 (en) |
| CA (1) | CA3007613A1 (en) |
| IL (1) | IL259857A (en) |
| MX (1) | MX2018006518A (en) |
| SG (2) | SG11201804473RA (en) |
| TW (1) | TW201726169A (en) |
| WO (1) | WO2017099034A1 (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019025188A2 (en) | 2017-06-01 | 2020-06-23 | Cytomx Therapeutics, Inc. | ACTIVABLE ANTI-PDL1 ANTIBODIES AND METHODS OF USE OF THE SAME |
| US20200131270A1 (en) * | 2017-07-20 | 2020-04-30 | National University Corporation Hokkaido University | Combination use of inhibitor targeting pd-1/pd-l1 and cox-2 inhibitor |
| UA126458C2 (en) | 2018-02-13 | 2022-10-05 | Гіліад Сайєнсіз, Інк. | Pd-1/pd-l1 inhibitors |
| JPWO2019187673A1 (en) * | 2018-03-29 | 2021-04-08 | ソニー株式会社 | Information processing equipment, information processing methods and programs |
| JP7242702B2 (en) | 2018-04-19 | 2023-03-20 | ギリアード サイエンシーズ， インコーポレイテッド | PD-1/PD-L1 inhibitor |
| TWI732245B (en) | 2018-07-13 | 2021-07-01 | 美商基利科學股份有限公司 | Pd-1/pd-l1 inhibitors |
| WO2020086556A1 (en) | 2018-10-24 | 2020-04-30 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| WO2020169707A1 (en) * | 2019-02-21 | 2020-08-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Foxo1 inhibitor for use in the treatment of latent virus infection |
| RU2731293C1 (en) | 2019-04-12 | 2020-09-01 | Игорь Петрович Белецкий | Method of producing genetically modified lines of cells of natural killers with knockout pd-1 gene and high expression of proteins of family of tumour necrosis factor for immunotherapy of oncological diseases |
| US20220401385A1 (en) * | 2019-11-13 | 2022-12-22 | Kyoto University | Combination Therapy Based on PD-1 Signaling Inhibitors |
| EP4204008A1 (en) | 2020-08-26 | 2023-07-05 | Citius Pharmaceuticals, Inc. | Combination for use in methods of treating cancer |
| CN112472710A (en) * | 2020-11-05 | 2021-03-12 | 中国人民解放军海军军医大学 | Application of nicotinamide adenine dinucleotide precursor in preparation of anti-tumor sensitization medicine of immune checkpoint inhibitor |
| WO2022197554A1 (en) * | 2021-03-16 | 2022-09-22 | University Of Massachusetts | Photocaged citrulline analogs and methods for site-specific incorporation of citrulline into proteins |
| CN113069529A (en) * | 2021-04-16 | 2021-07-06 | 郑州大学第一附属医院 | Use of GSH in combination with PD-1/PD-L1 blockers for promoting CD8+Use of T cell function |
| WO2023076880A1 (en) * | 2021-10-25 | 2023-05-04 | Board Of Regents, The University Of Texas System | Foxo1-targeted therapy for the treatment of cancer |
| CN115414343B (en) * | 2022-09-29 | 2023-11-21 | 中南大学湘雅医院 | Application of alpha-ketoglutaric acid and derivatives thereof and medicine for preventing and treating skin tumor |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1214040A4 (en) * | 1999-09-21 | 2004-06-23 | Univ Rutgers | Extracts of orange peel for prevention and treatment of cancer |
| KR20030067935A (en) * | 2002-02-09 | 2003-08-19 | 김상건 | Pharmaceutical Composition Comprising Oltipraz for Regeneration of Cirrhotic Liver |
| US20150329617A1 (en) * | 2001-03-14 | 2015-11-19 | Dynal Biotech Asa | Novel MHC molecule constructs, and methods of employing these constructs for diagnosis and therapy, and uses of MHC molecules |
| KR20110120981A (en) * | 2002-12-26 | 2011-11-04 | 아지노모토 가부시키가이샤 | Inhibitor for liver cancer onset and progress |
| JP5248747B2 (en) * | 2006-01-19 | 2013-07-31 | キッセイ薬品工業株式会社 | Adiponectin receptor expression activator |
| JP6041333B2 (en) * | 2011-01-13 | 2016-12-07 | 学校法人近畿大学 | Antitumor agent |
| KR20150041786A (en) * | 2012-07-10 | 2015-04-17 | 바실리어 파마슈티카 아게 | Combination therapy for the treatment of cancer and immunosuppression |
| DK2897620T3 (en) * | 2012-09-21 | 2020-08-17 | Intensity Therapeutics Inc | CANCER TREATMENT PROCEDURE |
| EP3083692B1 (en) * | 2013-12-17 | 2020-02-19 | F.Hoffmann-La Roche Ag | Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies |
| JP6104417B2 (en) | 2016-02-02 | 2017-03-29 | キヤノン株式会社 | Control device, control method, and program |
-
2016
- 2016-12-05 EP EP16872932.5A patent/EP3388084A4/en not_active Withdrawn
- 2016-12-05 BR BR112018011131-7A patent/BR112018011131A2/en not_active IP Right Cessation
- 2016-12-05 KR KR1020187019345A patent/KR20180093990A/en unknown
- 2016-12-05 CN CN202111427435.0A patent/CN114404595A/en active Pending
- 2016-12-05 SG SG11201804473RA patent/SG11201804473RA/en unknown
- 2016-12-05 AU AU2016366250A patent/AU2016366250A1/en not_active Abandoned
- 2016-12-05 CN CN201680081286.8A patent/CN108601840A/en active Pending
- 2016-12-05 MX MX2018006518A patent/MX2018006518A/en unknown
- 2016-12-05 WO PCT/JP2016/086045 patent/WO2017099034A1/en active Application Filing
- 2016-12-05 JP JP2017555054A patent/JP6994240B2/en active Active
- 2016-12-05 EP EP23158416.0A patent/EP4218819A3/en active Pending
- 2016-12-05 CN CN202111427571.XA patent/CN114601930A/en active Pending
- 2016-12-05 CA CA3007613A patent/CA3007613A1/en not_active Abandoned
- 2016-12-05 SG SG10202006032VA patent/SG10202006032VA/en unknown
- 2016-12-05 US US16/060,317 patent/US20180362650A1/en not_active Abandoned
- 2016-12-07 TW TW105140511A patent/TW201726169A/en unknown
-
2018
- 2018-06-06 IL IL259857A patent/IL259857A/en unknown
-
2022
- 2022-10-13 US US18/046,300 patent/US20230265193A1/en active Pending
- 2022-10-13 US US18/046,277 patent/US20230272077A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017099034A1 (en) | 2017-06-15 |
| AU2016366250A1 (en) | 2018-06-14 |
| CN114601930A (en) | 2022-06-10 |
| CN108601840A (en) | 2018-09-28 |
| TW201726169A (en) | 2017-08-01 |
| MX2018006518A (en) | 2019-01-10 |
| JP6994240B2 (en) | 2022-02-04 |
| US20230272077A1 (en) | 2023-08-31 |
| EP3388084A4 (en) | 2019-11-13 |
| US20180362650A1 (en) | 2018-12-20 |
| CN114404595A (en) | 2022-04-29 |
| IL259857A (en) | 2018-07-31 |
| BR112018011131A2 (en) | 2018-11-21 |
| EP4218819A2 (en) | 2023-08-02 |
| EP4218819A3 (en) | 2023-08-23 |
| CA3007613A1 (en) | 2017-06-15 |
| JPWO2017099034A1 (en) | 2018-11-01 |
| SG11201804473RA (en) | 2018-06-28 |
| EP3388084A1 (en) | 2018-10-17 |
| US20230265193A1 (en) | 2023-08-24 |
| KR20180093990A (en) | 2018-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL259857A (en) | Pd-1 signal inhibitor combination therapy | |
| IL287113A (en) | Smyd inhibitors | |
| IL259560A (en) | Inhibitors of the menin-mll interaction | |
| IL250642B (en) | Glycosidase inhibitors | |
| HK1244792B (en) | Necrosis inhibitors | |
| IL249476A0 (en) | Combination therapy with glutaminase inhibitors | |
| IL246362A0 (en) | Novel glutaminase inhibitors | |
| GB201421083D0 (en) | Enzyme inhibitors | |
| HK1243415A1 (en) | Bromodomain inhibitors | |
| EP3116872A4 (en) | Combination therapy with glutaminase inhibitors | |
| EP3116503A4 (en) | Hptp-beta inhibitors | |
| IL251932B (en) | Benzylpropargylether as nitrification inhibitors | |
| AP2016009371A0 (en) | Benzimidazol-2-amines as midh1 inhibitors | |
| IL248895A0 (en) | Phosphatidylinositol -kinase inhibitors | |
| HK1244480A1 (en) | Necrosis inhibitors | |
| IL265139B (en) | Dopamine-b-hydroxylase inhibitors | |
| ZA201907136B (en) | Ip6k inhibitors | |
| GB201612860D0 (en) | Inhibitors | |
| GB201501004D0 (en) | Inhibitors | |
| GB2538450B (en) | Signal system | |
| IL242157B (en) | Pulse amplifier | |
| HK1244790A1 (en) | Bace1 inhibitors | |
| IL274550A (en) | Dopamine-b-hydroxylase inhibitors | |
| GB201401005D0 (en) | Inhibitor | |
| GB201520949D0 (en) | Inhibitors |